The DOI matches its Crossref record; 131 of the 132 references it cites were found in a registry or an index; 79 of the 113 sources its claims cite were checked for support.
The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry
Open accessAbstract
The etiology of psychiatric disorders is complex, involving both genetic and environmental factors with emerging evidence suggesting that epigenetic modifications, including DNA methylation, histone modifications, and non-coding RNA regulation, significantly contribute to mental health. The epigenome influences the development of psychiatric disorders and human behavior and may be considered in clinical observations. Epigenetic changes have been well-established in BDNF , COMT , FKBP5 , NR3C1 , SLC6A4 , and DRD2 , genes associated with psychiatric disorders, including schizophrenia, major depressive disorder (MDD), bipolar disorder (BP), post-traumatic stress disorder (PTSD), and autism spectrum disorder (ASD). Therefore, these epigenetic marks have the potential to be suitable biomarkers for diagnostics, as predictors of prognosis, and for the development of personalized treatments. By exploring the role of clinically relevant epigenetic genes, we review the role of the epigenome in the context of psychiatric disorders and human behavior; and we consider that these changes may be observed in the context of precision psychiatry. This review synthesizes findings from over 100 original research articles and reviews spanning a range of clinical studies. Despite promising associations, challenges in the onset of precision psychiatry, such as tissue heterogeneity, small sample sizes, and lack of replication, are likely to limit translation into clinical practice. Future research in precision psychiatry will help identify clinically actionable epigenetic biomarkers, ushering in an era of genomic medicine in psychiatry.
Overview
CoChat Summary
TL;DR
This narrative review summarizes epigenetic mechanisms—DNA methylation, histone modifications, non-coding RNAs, and chromatin remodeling—and their roles in psychiatric disorders, focusing on BDNF, COMT, FKBP5, NR3C1, SLC6A4, and DRD2. It argues these marks may support precision psychiatry as biomarkers for diagnosis, prognosis, and treatment response, but translation is limited by tissue heterogeneity, small samples, lack of replication, and other methodological challenges.
Key findings
- Epigenetic changes are well-established in BDNF, COMT, FKBP5, NR3C1, SLC6A4, and DRD2 and are associated with schizophrenia, MDD, bipolar disorder, PTSD, ASD, ADHD, OCD, AUD, and SUD. Examples include BDNF promoter hypermethylation reducing BDNF expression, NR3C1 exon 1F hypermethylation after childhood adversity impairing glucocorticoid receptor/HPA-axis regulation, and FKBP5 demethylation/upregulation linked to stress reactivity.
- Epigenetic marks have potential clinical utility as biomarkers for diagnostics, prognosis, relapse risk, and personalized treatment. The review states that methylation of NR3C1, BDNF, and FKBP5 may differentiate subtypes of MDD, PTSD, or schizophrenia; low BDNF methylation correlates with better SSRI response, and high NR3C1 methylation predicts poorer CBT response in PTSD.
- Experimental epigenetic therapies include HDAC inhibitors such as valproic acid, sodium butyrate, and Vorinostat (SAHA); BET inhibitor JQ1; miRNA-based therapies involving miR-124, miR-132, miR-135, and miR-146a; and CRISPR/dCas9 epigenetic editing approaches, mostly in preclinical models.
- The review synthesizes findings from over 100 original research articles and reviews. It concludes that challenges such as tissue heterogeneity, small sample sizes, and lack of replication are likely to limit translation into routine clinical practice.
Methods
- Narrative review of clinically relevant epigenetic mechanisms, candidate genes, and precision psychiatry applications.
- The paper states it synthesizes findings from over 100 original research articles and reviews spanning a range of clinical studies.
- No primary data collection or systematic quantitative synthesis is reported; the review summarizes mechanistic, candidate-gene, and clinical-implication literature.
Limitations
- Stated: limited access to brain tissue means sampling often relies on blood, saliva, or postmortem samples that may not reflect CNS changes; cell-type specificity and bulk tissue analyses can obscure cellular differences; epigenetic marks are dynamic and temporally variable; different assays can yield inconsistent results; large-scale reference datasets are predominantly from individuals of European ancestry; confounders include lifestyle, socioeconomic factors, substance use, and comorbid medical conditions; epigenetic findings are not yet validated for routine psychiatric practice; and an exclusive focus on epigenetics risks oversimplifying disease etiology.
- Evident from the text: as a narrative review, it does not report a systematic search strategy, formal study-quality assessment, or quantitative meta-analysis, which limits reproducibility and strength of conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Valid · 16 Not valid · 29 Not checked · 20 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“For example, clinical studies suggest that low BDNF methylation correlates with better SSRI response and high NR3C1 methylation predicts poorer CBT response in PTSD (56).”
§ The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry > Clinical implications of epigenetics in psychiatry > Precision psychiatry and future directions
What the sources say
- Disputedcites [56] Yehuda, 2013, Epigenetic biomarkers as predictors and correlates of symptom improvement following psychotherapy in combat veterans with PTSD, Front Psychiatry sourceExperimental — accuracy not yet measured
The ‘Methylation of a GR Promoter’ section reports the opposite direction: veterans who responded had higher pretreatment NR3C1 promoter methylation than non-responders, and higher methylation corresponded to lower post-treatment PTSD symptom scores. The study examined prolonged exposure psychotherapy, not CBT; page numbers are unavailable in our copy. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“higher BDNF levels are associated with improved cognitive performance including memory, attention, and problem-solving”
§ The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry > Clinically relevant epigenetically regulated genes in psychiatry > Brain-derived neurotrophic factor
What the sources say
- Partly supportedcites [60] Egan, 2003, The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function, Cell sourceExperimental — accuracy not yet measured
The Results (page unavailable) link BDNF genotype to verbal episodic-memory scores, and the Discussion links the variant to altered activity-dependent BDNF secretion. The paper does not establish that higher BDNF levels improve cognitive performance generally, including attention and problem-solving; the Results report no significant genotype effect on working memory or executive function. (LLM, conf=0.89)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In depression, altered chromatin accessibility have been observed at BDNF, GAD1, NR3C1 in response to stress”
§ The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry > Epigenetic mechanisms in psychiatry > Chromatin remodeling
What the sources say
- Partly supportedcites [43] Labonté, 2012, Genome-wide epigenetic regulation by early-life trauma, Arch Gen Psychiatry sourceExperimental — accuracy not yet measured
The passage labeled Abstract (page unavailable) describes stress-related promoter hypermethylation involving BDNF, GAD1, and glucocorticoid-receptor variants, including methylation that constrains transcription-factor binding. It does not establish altered chromatin accessibility at all three genes in people with depression: the BDNF and GAD1 examples concern stressed rats, while the human example concerns suicide completers with childhood abuse. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In PTSD, increased COMT methylation is associated with impaired fear inhibition, which affects stress responsivity via dopamine regulation”
§ The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry > Clinically relevant epigenetically regulated genes in psychiatry > Catechol-O-methyltransferase
What the sources say
- Partly supportedcites [79] Norrholm, 2013, Differential genetic and epigenetic regulation of catechol-O-methyltransferase is associated with impaired fear inhibition in posttraumatic stress disorder, Front Behav Neurosci sourceExperimental — accuracy not yet measured
The Results (Methylation) and Discussion report that higher COMT promoter methylation was associated with greater fear responses to a safety signal, consistent with impaired fear inhibition in the study’s traumatized participants. The Introduction describes COMT’s role in clearing dopamine, but the paper does not establish that the methylation-associated fear-inhibition difference affects stress responsivity through dopamine regulation. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“methylation of the COMT promoter has been associated with reduced gene expression in both brain and peripheral tissues, leading to increased dopamine availability in the prefrontal cortex”
§ The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry > Clinically relevant epigenetically regulated genes in psychiatry > Catechol-O-methyltransferase
What the sources say
- Could not verifycites [75] Drabe, 2017, Serotonin transporter gene promoter methylation status correlates with in vivo prefrontal 5-HTT availability and reward function in human obesity, Transl Psychiatry sourceExperimental — accuracy not yet measured
The Results and Discussion passages concern methylation of the serotonin transporter gene (5-HTTLPR/SLC6A4) and prefrontal 5-HTT availability, not COMT or dopamine. Searches for COMT and COMT promoter methylation found no passage addressing reduced COMT expression in brain or peripheral tissue or increased prefrontal dopamine availability. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
77 more claims · 45 with their cited sources checked
Create a free account to see all 118 claims and every source verdict.
- It may state two separate claims as one. 34
- Probably not a substantial claim. 4
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry > Epigenetic mechanisms in psychiatry > Environmental influence on epigenetic changes
“In the case of early-life stress, commonly experienced through childhood abuse, DNA methylation of stress-regulating genes (i.e. NR3C1, FKBP5) increases, hypermethylating the glucocorticoid receptor and altering the HPA axis (10).”
§ The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry > Clinically relevant epigenetically regulated genes in psychiatry > FK506 binding protein 5
“Stress exposure such as early-life stress decreases methylation of FKBP5 and upregulates FKBP5 gene expression which reduces GR sensitivity and may cause an exaggerated stress response (85).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry > Introduction
“These changes to the DNA sequence include epigenetic mechanisms that are readily reversible spanning from DNA methylation, histone modifications to non-coding RNAs and chromatin remodeling (3, 4).”
§ The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry > Epigenetic mechanisms in psychiatry
“Epigenetic modifications are readily reversible changes that influence gene expression without altering the DNA sequence (3).”
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325 · cited 2×
“These mechanisms act as molecular switches or dimmers, turning genes on or off in response to internal and external stimuli (7).”
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162 · cited 1×
“The SLC6A4 gene encodes the serotonin transporter (SERT), a membrane protein responsible for the reuptake of serotonin (5-HT) from the synaptic cleft back into presynaptic neurons (100).”
DNA methylation and its basic function
Moore, L. D., Le, T., & Fan, G. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.112 · Cited by 4,906 · cited 1×
“…process by which DNA methyltransferases (DNMTs) catalyze the addition of a methyl group (-CH 3 ) to cytosine residues on the 5-carbon of the cytosine ring in CpG dinucleotides, cytosine-rich regions often near gene promoters, between genes (referred to as intergenic regions), or in gene bodies (8).”
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672 · cited 1×
“…gene expression post-transcriptionally by binding to target messenger RNAs (mRNAs) and suppress translation or promote mRNA degradation (29). miRNAs are both targets and regulators of epigenetic processes since they exist within a feedback loop with DNA methylation and histone modi fi cations (30).”
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse
McGowan, P. O., Sasaki, A., D'Alessio, A. C., Dymov, S., Labonté, B., Szyf, M., Turecki, G., & Meaney, M. J. (2009) · Nature Neuroscience · doi:10.1038/nn.2270 · Cited by 3,531 · cited 2×
“In psychiatry, this dynamic process where methylation is readily added or removed occurs in response to developmental cues and environmental exposures such as stress, trauma, and aging (10).”
Cited by
Makarewicz, A., Recław, R., Grzywacz, A., Chmielowiec, J., & Chmielowiec, K. (2026) · Brain Sciences · doi:10.3390/brainsci16020187 · Cited by 2
Concurrent Serial Feature Negative and Simple Discrimination Training and Testing in the Mouse
Ardabili, N. G., Pettiford, J., Hyde, A., Airosus, C., Riley, A. L., & Davidson, T. L. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116100
Epigenetics of bipolar disorder: a bibliometric landscape and visualization analysis
Xiong, L., Fan, H., Gao, J., & Lei, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1804155
Advancing Our Understanding of Depression—From Molecular Mechanisms to Novel Therapeutic Frontiers
Kisková, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188069
Metadata
- Authors
- Montel Hayes, R., Mason, C. E., & Miller, J. J.
- Affiliations
- Cornell University (US)
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2025-10-29
- Volume
- 16
- Pages
- 1671122-1671122
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC12605923
- OpenAlex
- W4415663958
- Cited by
- 5
- References
- 131
- Citations by year
- 2026: 5
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- epigenetics, mental illness, precision psychiatry, DNA methylation, histone modifications, non-coding RNA, candidate genes, brain-derived neurotrophic factor, catechol-O-methyltransferase, FKBP5, NR3C1, serotonin transporter, DRD2, schizophrenia, major depressive disorder, bipolar disorder, post-traumatic stress disorder, autism spectrum disorder, epigenetic biomarkers, personalized treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry. https://app.cochat.ai/papers/10.3389/fpsyt.2025.1671122
- The paper
- Montel Hayes, R., Mason, C. E., & Miller, J. J. (2025). The clinical use of epigenetics in psychiatry: a narrative review of epigenetic mechanisms, key candidate genes, and precision psychiatry. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2025.1671122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.